Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, Ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. BioSim? Vedolizumab ELISA kit is a Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtitre plate coated with the reactant for Ramucirumab (Cyramza?). After incubation, the wells are wa
Size
96 assays
Concentration
n/a
Applications
Sensitivity: 20 ng/ml,Detection Range: 20 - 600 ng/ml,Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100),Cross Reactivity: Except for Ramucirumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins.,This ELISA kit is used for in vitro quantitative determination of Ramucirumab,Recovery rate: 85 - 115% with normal human serum samples with known concentrations